MedPageToday -- SAN FRANCISCO -- A randomized trial of liposomal irinotecan (PEP02) in gastric cancer yielded mixed results, achieving the primary objective of tumor shrinkage but without improving disease control rates or survival.
MedPageToday -- SAN FRANCISCO -- A randomized trial of liposomal irinotecan (PEP02) in gastric cancer yielded mixed results, achieving the primary objective of tumor shrinkage but without improving disease control rates or survival.
